Public Employees Retirement System of Ohio Has $284,000 Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV)

Public Employees Retirement System of Ohio grew its holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) by 27.3% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 58,700 shares of the company’s stock after acquiring an additional 12,600 shares during the quarter. Public Employees Retirement System of Ohio owned 0.07% of Verve Therapeutics worth $284,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of VERV. Cornercap Investment Counsel Inc. increased its stake in Verve Therapeutics by 13.5% during the 2nd quarter. Cornercap Investment Counsel Inc. now owns 14,956 shares of the company’s stock worth $73,000 after acquiring an additional 1,778 shares during the period. Arizona State Retirement System increased its position in shares of Verve Therapeutics by 14.1% in the second quarter. Arizona State Retirement System now owns 16,386 shares of the company’s stock worth $80,000 after purchasing an additional 2,019 shares during the period. Accredited Investors Inc. raised its stake in Verve Therapeutics by 14.3% in the third quarter. Accredited Investors Inc. now owns 20,000 shares of the company’s stock valued at $97,000 after purchasing an additional 2,500 shares in the last quarter. FMR LLC lifted its position in Verve Therapeutics by 0.3% during the third quarter. FMR LLC now owns 1,418,993 shares of the company’s stock worth $6,868,000 after purchasing an additional 3,873 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Verve Therapeutics by 20.4% during the second quarter. The Manufacturers Life Insurance Company now owns 28,105 shares of the company’s stock worth $137,000 after buying an additional 4,759 shares in the last quarter. 97.11% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on VERV. Canaccord Genuity Group upped their price target on shares of Verve Therapeutics from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, November 6th. HC Wainwright cut their target price on Verve Therapeutics from $15.00 to $14.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Finally, Royal Bank of Canada decreased their price target on Verve Therapeutics from $20.00 to $17.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th.

Verve Therapeutics Price Performance

VERV stock opened at $5.74 on Friday. The stock has a market cap of $485.97 million, a price-to-earnings ratio of -2.33 and a beta of 1.71. The company has a 50 day simple moving average of $5.78 and a 200 day simple moving average of $5.66. Verve Therapeutics, Inc. has a 1 year low of $4.30 and a 1 year high of $19.34.

Verve Therapeutics (NASDAQ:VERV) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.70) by $0.11. The company had revenue of $6.87 million during the quarter, compared to the consensus estimate of $2.75 million. Verve Therapeutics had a negative net margin of 807.65% and a negative return on equity of 35.23%. The company’s revenue for the quarter was up 120.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.72) earnings per share. On average, equities research analysts anticipate that Verve Therapeutics, Inc. will post -2.49 EPS for the current fiscal year.

Verve Therapeutics Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.